Medtronic announced U.S. commercial availability of its MiniMed Connect mobile accessory for Android

Medtronic announced U.S. commercial availability of its MiniMed Connect mobile accessory for Android

The MiniMed Connect mobile accessory, now available for Android devices, is the first product to enable people with diabetes to discreetly and conveniently view their insulin pump and CGM information on a smartphone.

MiniMed Connect Mobile Accessory Provides Easier and Better Access to Pump and CGM Data, Helping Optimize Therapy for Improved Glycemic Patterns

DUBLIN, 27-Oct-2016 — /EuropaWire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of the Android(TM) operating system version of the MiniMed Connect mobile accessory, the first and only product enabling people with diabetes to see their real-time glucose level  on Android mobile devices.

The MiniMed Connect app, which was originally launched on iOS in September 2015, helps people with diabetes see how they’re doing right on their phone by providing convenient access to their insulin pump and CGM (continuous glucose monitoring) data in an easy-to-use smartphone application.  The MiniMed Connect app also allows care partners to better participate in diabetes care with real-time access to glucose and insulin data on any Internet-connected mobile device or PC and therapy alerts via text message.  In addition, the MiniMed Connect app allows healthcare providers to more efficiently access data for therapy optimization through daily uploads of insulin and CGM information into CareLink® therapy management software.

The MiniMed Connect app enables people with diabetes and their healthcare providers to better optimize therapy, leading to improved glycemic patterns. In a retrospective analysis of CareLink data1 on nearly 2,800 patients, use of the MiniMed Connect app resulted in:

  • Two fewer severe low blood sugar events (<50 mg/dl for more than 20 minutes) per year
  • Forty-one fewer severe high blood sugar events (>300 mg/dl for more than 20 minutes) per year
  • 66 percent of patients stayed in range more often

“In addition to greater convenience, our recent data shows that with easier and better access to their data, the MiniMed Connect app helps patients reduce high and low sugar events, and keep their sugar within range more often,” said Annette Brüls, president, Diabetes Service and Solutions business at Medtronic. “Making the MiniMed Connect app available for Android users, their loved ones and their care partners propels us forward in our goal to meet both the diabetes management and lifestyle needs of people with diabetes so they can live with greater freedom and better health.”

“For individuals with diabetes, the need to constantly monitor sugar levels can be cumbersome and far from discreet,” said Dr. David Rhew, chief medical officer and head of healthcare and fitness at Samsung. “Working with Medtronic, we are harnessing the power of industry leading mobile technology to make diabetes management less stressful and more seamless for the millions of Americans living with the condition. Samsung is thrilled to partner with Medtronic to launch the first-of-its-kind MiniMed Connect application on Android, which has been tested and approved for use on many of Samsung’s flagship smartphones including the Samsung Galaxy S7 and Galaxy S7 Edge.”

The MiniMed Connect app is compatible with both the MiniMed® 530G system and the MiniMed® Revel(TM) system, providing greater convenience for people with diabetes, greater peace of mind for their care partners, and more convenient access to diabetes data for healthcare teams.

  • People with diabetes can discreetly view their diabetes information on a smartphone  application.
  • The MiniMed Connect app allows care partners to view and monitor this diabetes information via CareLink Personal software, delivering preset text notifications to care partners when the person with diabetes experiences sugar levels that go too high or too low or when an alarm on the pump isn’t cleared.
  • With patient permission, and as arranged with their healthcare providers, there can be convenient access to diabetes data in the CareLink reports.
  • The MiniMed Connect app for Android will work on a wide variety of Android devices including Samsung Galaxy S7 and Galaxy S7 Edge which are among best-selling smartphones in the world for 20162.

Medtronic’s vision is to transform diabetes care, together for greater freedom and better health. This vision is centered around a deep-rooted belief in delivering solutions so that people with diabetes can live their exceptional lives. The MiniMed Connect app achieves this objective and is also a further demonstration of how Medtronic is moving beyond insulin pumps and CGM devices and integrating leading consumer technologies, data and informatics to enable better therapy decision-making and care.

About the Diabetes Group at Medtronic (
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


1 Retrospective analysis of data uploaded to CareLink database for 2,794 patients using the MiniMed Connect device and app for at least 60 days, collected from September 2015 to May 2016. Data is compared to prior 60 days of CareLink data before using MiniMed Connect app. All data based on sensor glucose measurements.

2 Kantar Worldpanel data

Pamela Reese
Public Relations

Ryan Weispfenning
Investor Relations

SOURCE: Medtronic plc


Comments are closed.